This review outlines consensus-based recommendations for consideration of allogeneic hematopoietic cell transplantation (HCT) in primary myelofibrosis. Among the recommendations are that patients with intermediate-2- or high-risk disease and age <70 years be considered as candidates for allo-HCT. The authors recommend that patients with intermediate-1-risk disease and age <65 years be considered as candidates for allo-HCT if they present with either refractory, transfusion-dependent anemia, or a percentage of blasts in peripheral blood >2%, or adverse cytogenetics.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: Indications for Allo-HCT in Primary Myelofibrosis
Oct 2015